Alnylam Pharmaceuticals (ALNY) reported Q1 non-GAAP net loss Thursday of $0.01 per diluted share, narrower than the $0.16 net loss a year earlier.
Analysts polled by FactSet expected a loss of $0.38.
Revenue for the quarter ended March 31 was $594.2 million, up from $494.3 million a year earlier.
Analysts surveyed by FactSet expected $588.4 million.
The company reiterated its full-year 2025 guidance of $2.05 billion to $2.25 billion for total net product revenue, and $650 million to $750 million for net revenue from collaborations and royalties.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。